Comparative Effectiveness Bill Could Mean Opportunities For OTC Sponsors
This article was originally published in The Tan Sheet
Executive Summary
Interest on Capitol Hill in comparative effectiveness research could lead to opportunities for marketers of OTC drugs that compete with prescription drugs or other interventions